المتخصصون في المجالات الطبية

June 11, 2026

Although laryngeal papillomatosis is typically benign, it follows a recurrent and occasionally aggressive course with a rare risk of malignant transformation as a localized form of recurrent respiratory papillomatosis. Through histologic subtyping and longitudinal management, Mayo Clinic laryngologists tailor papillomatosis treatment with the goals of preserving laryngeal function and reducing disease burden.

"Early referral to a specialist is critical, especially when airway symptoms are present," says Amy L. Rutt, D.O., an otolaryngologist specializing in laryngeal surgery and voice disorders at Mayo Clinic in Jacksonville, Florida. "Patients should be prepared for a chronic but very manageable disease course."

Clinical presentation of laryngeal papillomatosis

Laryngeal papillomatosis can present in pediatric and adult populations. Patients with suspected disease often have a history of recurrent benign vocal fold lesions or prior operations. While symptoms may fluctuate daily, common presenting symptoms include:

• Dyspnea, especially in pediatric patients.
• Hemoptysis.
• Progressive and persistent hoarseness.
• Rapid voice deterioration.
• Stridor.

Laryngoscopic appearance of laryngeal papillomatosis

On laryngoscopy, papillomas grossly appear as multifocal, irregular and exophytic lesions with a vascular core. This appearance contrasts with the smoother morphology of many nodules and polyps or the keratotic features of leukoplakia. While papillomas can occur in any part of the larynx, they primarily affect the vocal folds and are commonly found in the supraglottis.

Choosing between awake biopsy and operative diagnosis with treatment

Mayo Clinic laryngologists take an individualized diagnostic approach. An awake biopsy is typically considered for patients with small, easily accessible lesions involving the middle or posterior aspects of the vocal folds. This approach is contraindicated in pediatric populations, as patients must be able to tolerate an awake laser procedure.

Common indications for operative diagnosis and treatment under general anesthesia include:

• Bilateral or extensive papillomatosis.
• Obstructed airways.
• Significant dysphonia.

"Another type of patient you would take to the operating room is someone where you want precision — if you are using a laser or a microdebrider, or if there is a lot of growth near the anterior commissure," Dr. Rutt says.

Surgical debulking techniques for laryngeal papillomas

Laryngologists use several excision and ablation techniques to debulk laryngeal papillomas, including:

• Blue light laser.
• Carbon-dioxide laser.
• Cold instruments.
• Microdebrider.
• Potassium titanyl phosphate laser.

The technique selected depends on the disease distribution, need for precision, surgeon expertise and available resources. Mayo Clinic laryngologists often use a blue light laser, which is well absorbed by the blood supply of laryngeal papillomas. It also provides a versatile option, allowing for the in-office treatment of smaller lesions and operative management of extensive lesions.

Optimizing disease control and voice preservation in papillomatosis

Laryngeal papillomatosis treatment should focus on safe debulking followed by voice reassessment before further intervention. Staged procedures are often necessary to balance disease control and voice preservation in individuals with significant vocal impairment and extensive lesions, especially when bilateral or near the anterior vocal folds.

"You need to be very careful near the anterior commissure region when treating these lesions. Being overly aggressive can cause persistent dysphonia or webbing and scarring, which is even more difficult to treat," Dr. Rutt says. "Whenever possible, you also want to preserve the very delicate superficial lamina propria."

Mayo Clinic laryngologists incorporate speech-language pathology into postoperative care. While complete eradication of dysphonia is unlikely, voice therapy can support patients in maintaining a functional voice.

Monitoring laryngeal papillomatosis recurrence

Papillomatosis requires long-term surveillance, including periodic laryngoscopy to monitor for new growths or CT chest scans to assess developing respiratory symptoms. Longitudinal follow-up varies depending on patient access to care, the extent of disease and recurrence rate.

Most patients require multiple repeat operations over time. Evidence suggests that adjuvant human papillomavirus (HPV) vaccination reduces recurrence rates and prolongs the interval between surgeries, leading Mayo Clinic laryngologists to recommend vaccination for all eligible patients.

"It is really important to counsel patients about recurrence," Dr. Rutt says. "This is typically a chronic disease. The goal is to control the disease, not cure it."

Using HPV subtyping to guide surveillance

Mayo Clinic laryngologists routinely request HPV subtyping from pathology to help understand individual risk and disease characteristics. Low-risk HPV types 6 and 11 account for most benign laryngeal papillomas, while HPV 11 is specifically linked to distal airway spread, primarily in early-onset disease.

HPV types 16 and 18 typically cause lesions with a high risk of malignant transformation into squamous cell carcinoma, warranting more-frequent surveillance to monitor cancer risk. Additional risk factors include prior head and neck cancer and excessive smoking or alcohol use.

When to consider adjuvant therapy in papillomatosis

Adjuvant therapy use varies among laryngologists. Specialists may recommend intralesional or systemic medications for patients with aggressive, rapidly recurring or distally spreading papillomatosis, particularly when more than four surgical interventions a year are required.

Mayo Clinic laryngologists are actively investigating the safety and immunogenicity of a dendritic cell vaccine for papillomatosis. In 2025, the Food and Drug Administration approved a new immunotherapy, zopapogene imadenovec-drba, which protects against cells infected with HPV 6 and 11.

"We are in the process of obtaining this new medicine so we can treat our patients with the latest therapy and reduce disease burden," Dr. Rutt says. "It's a wonderful breakthrough."

For more information

Refer a patient to Mayo Clinic.